Human Papillomavirus (HPV) Infection Vaccines Market Best Productivity Supply Chain Relationship, Development by 2026
Human papillomavirus
infection is most common sexually transmitted infection caused by
HPV-related cancers such as cervical and genital cancer. Human
papillomavirus infection vaccines are used to prevent genital wart,
anal cancer, cervical cancer, and vaginal cancer. Three commercially
available HPV prevention vaccine such as Gardasil and Gardasil 9 by
Merck & Co., Inc. and Cervarix by GlaxoSmithKline plc, are proven
to be highly effective in preventing of HPV infection and genital
precancerous lesions. The adoption of preventive vaccines shifted the
paradigm of diseases, and are expected to have a major impact in
reducing the burden of cervical cancer, HPV-associated malignancies,
and benign tumors. The key factors driving growth of the human
papillomavirus infection vaccine market include large number of
pipeline products, increasing research for therapeutic vaccine,
governmental initiative for immunization program, and high prevalence
of HPV-related infectious disease.
Request For
Sample Pdf Of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1588
Human
Papillomavirus (HPV) Infection Vaccines Market Driver
Large number of
clinical trials conducted by pharmaceutical and biopharmaceutical
companies are expected to fuel growth of the HPV infection vaccine
market during the forecast period. For instance, Merck & Co.,
Inc., is conducting Phase III clinical trial for it quadrivalent
human papillomavirus recombinant vaccine for type 6, 11, 16, and 18.
Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in
evaluating safety and primary immunogenicity of the quadrivalent
human papillomavirus vaccine in female population of China. Currently
studies are in phase I clinical trial. Furthermore, Serum Institute
of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is
expected to provide protection of around 90% against HPV infections,
which are prevalent in the emerging economies such as India and
China.
Moreover, increasing
research on therapeutic vaccine for treatment of HPV infection to
address unmet medical need is expected to boost growth of the human
papilloma virus (HPV) infection vaccines market. For instance,
Profectus BioSciences, Inc., is engage in developing GeneVax
prime/VesiculoVax, a therapeutic vaccine for HPV infection. The
vaccine is expected to be effective against seven HPV types.
Moreover, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as
candidate for immunotherapy to demonstrate efficacy against cervical
HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA
plasmid-based therapeutic vaccine, which completed phase 2b clinical
trial in 2015 and initiated phase 3 in June 2017.
Governmental and
non-governmental organization plays important role in increasing
awareness through immunization program, in turn driving growth of the
human papillomavirus infection vaccine market. For instance, in 2012,
the Global Alliance for Vaccines and Immunization (GAVI) support for
HPV vaccine introduction targeted to reach 30 million girls in
emerging economies by 2020. In 2016, Joint UN Global Programme was
set up for prevention of cervical cancer, which includes vaccination
in high disease burden countries.
Human
Papillomavirus (HPV) Infection Vaccines Market Regional Analysis
Regional
segmentation of human papillomavirus (HPV) infection vaccine market
by Coherent Market Insights, includes North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa. North America
comprises major share of the human papillomavirus infection treatment
vaccine market, owing to high prevalence of cervical cancer, local
market players and increasing governmental initiatives, followed by
Europe. For instance, according to WHO 2016, currently 86% of America
and 62% of European region girls have access to free HPV vaccination.
Moreover, incidence of cervical cancer in Europe was 58,348
individuals per million in 2012.
Human
Papillomavirus (HPV) Infection Vaccines Market Key Players
Major players
operating in the HPV infection vaccine market include Merck &
Co., Inc. and GlaxoSmithKline plc. The companies having the candidate
for HPV vaccines are Shanghai Bovax Biotechnology Co., Ltd.,
Profectus BioSciences, Inc., 2A Pharma AB and ISA Pharmaceuticals.
Click To Read More On Human
Papillomavirus (HPV) Infection Vaccines Market
Also, Coherent
Market Insights has a proprietary database of pipeline biologics and
biosimilars, called PHASE-XS. This database provides analytical data
in addition to the clinical information of ongoing trials for
biologics and biosimilars. An amalgamation of more than 30
parameters, PHASE-XS helps biotechnology and pharmaceutical companies
to analyze the market trend, competition, and market potential. For
more information or to access this database, kindly click on the
below link or contact at sales@coherentmarketinsights.com
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Comments
Post a Comment